Medicenna Announces Compelling Survival Benefit from Phase 2b Study of Bizaxofusp in Recurrent Glioblastoma at the 28th Annual Meeting of the Society for NeuroOncology
Stock Information for Medicenna Therapeutics Corp.
Loading
Please wait while we load your information from QuoteMedia.